Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIVISMO-1: Vismodegib Pharmacokinetics and Safety in Basal Cell Carcinoma
NCT03610022Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Sep 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of vismodegib in basal cell carcinoma (BCC), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Sep 2018; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT03610022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610022.